|
[1]Bonow RO, Smaha LA, Smith SC, Mensah GA, Lenfant C. World Heart Day 2002: the International Burden of Cardiovascular Disease: responding to the Emerging Global Epidemic. Circulation. 2002; 106: 1602-05. [2]World, Health, Organization. World Health Statistics 2006:1–80. 2006; August 15. [3]Libby P, Theroux P. Pathophysiology of Coronary Artery Disease. Circulation. 2005; 111: 3481-88. [4]Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868-74. [5]Libby P, Lee R. Matrix matters. Circulation. 2000; 102: 1874-6. [6]Williams K, Tabas I. The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol. 1998(9): 471-4. [7]Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med. 2001; 11: 142-7. [8]Tabas I. Nonoxidative modifications of lipoproteins in atherogenesis. Ann Rev Nutr. 1999; 19: 123-39. [9]Demer LL. Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. Int J Epidemiol. 2002; 31: 737-41. [10]Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol. 2002; 22: 1370-8-. [11]Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 2003; 9: 458-62. [12]Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am. 2000; 84: 149-61. [13]Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-9. [14]Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344: 1959-65. [15]Davies MJ. Stability, and instability: the two faces of coronary atherosclerosis: the Paul Dudley White Lecture. Circulation. 1995; 94: 2013-20. [16]Falk E, Shah P, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657-71. [17]Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the unstable plaque. Prog Cardiovasc Dis. 2002; 44: 349-56. [18]Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997; 95: 594-9. [19]Vaughan DE. Plasminogen activator inhibitor-1 and the calculus of mortality after myocardial infarction. Circulation. 2003; 108: 376-7. [20]Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies, part I. Circulation. 2003; 108: 1664-72. [21]Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies, part II. Circulation. 2003; 108: 1772-8. [22]Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985; 71: 699-708. [23]Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000; 101: 570-80. [24]Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—2002: summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002; 106: 1893-900. [25]Xiao Z, Theroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol. 2004; 43: 1982-8. [26]Xiao Z, Theroux P, Frojmovic M. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor. Thromb Haemost. 1999; 81: 281-5. [27]Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002; 8: 1257-62. [28]Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-43. [29]Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20-8. [30]Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86(5): 494-501. [31]Andreassi MG, Botto N. DNA Damage as a New Emerging Risk Factor in Atherosclerosis. Trends Cardiovasc Med. 2003; 13: 270-5. [32]Cuong DV, Warda M, Kim N, Park WS, Ko JH, Kim E, et al. Dynamic changes in nitric oxide and mitochondrial oxidative stress with site-dependent differential tissue response during anoxic preconditioning in rat heart. American Journal of Physiology - Heart & Circulatory Physiology. 2007; 293(3): H1457-65. [33]Satoh M, Ishikawa Y, Takahashi Y, Itoh T, Minami Y, Nakamura M. Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease. Atherosclerosis. 2008; 198(2): 347-53. [34]Yurdakul S, Ozben B, Bilge AK, Turkoglu UM, Arkaya S, Nisanci Y. Oxidative DNA damage is significantly correlated with flow-mediated dilation in patients with coronary artery disease. J Invest Med. 2008; 56(7): 925-30. [35]Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, et al. Chemokines and Cardiovascular Risk. Arterioscler Thromb Vasc Biol. 2008; 28: 1909-19. [36]Thum T, Borlak J. LOX-1 receptor blockade abrogates oxLDL-induced oxidative DNA damage and prevents activation of the transcriptional repressor Oct-1 in human coronary arterial endothelium. J Biol Chem. 2008; 283(28): 19456-64. [37]Ramos KS, Partridge CR. Atherosclerosis and cancer: flip sides of the neoplastic response in mammalian cells? Cardiovasc Toxicol. 2005; 5: 245-55. [38]Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann NY Acad Sci. 2001; 947: 271–92, discussion 92–93. [39]Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA. 1973; 70: 1753-6. [40]Curfs DM, Lutgens E, Gijbels MJ, Kockx MM, Daemen MJ, vanSchooten FJ. Chronic exposure to the carcinogenic compound benzo[a]pyrene induces larger and phenotypically different atherosclerotic plaques in ApoE-knockout mice. Am J Pathol 2004; 164: 101-8. [41]Binkova B, Smerhovsky Z, Strejc P, Boubelik O, Stavkova Z, Chvatalova I, et al. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat Res. 2002; 501: 115-28. [42]Curfs DM, Knaapen AM, Pachen DM, Gijbels MJ, Lutgens E, Smook ML, et al. Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties. FASEB J 2005; 19: 1290-2. [43]Lecureur V, Ferrec EL, Ndiaye M, Vee ML, Gardyn C, Gilot D, et al. ERK-dependent induction of TNFalpha expression by the environmental contaminant benzo(a)pyrene in primary human macrophages. FEBS Lett. 2005; 579: 1904-10. [44]Ramos KS, Moorthy B. Bioactivation of polycyclic aromatic hydrocarbon carcinogens within the vascular wall: implications for human atherogenesis. Drug Metab Rev. 2005; 37: 595-610. [45]Ramadass P, Meerarani P, Toborek M, Robertson LW, Hennig B. Dietary flavonoids modulate PCB-induced oxidative stress, CYP1A1 induction, and AhR-DNA binding activity in vascular endothelial cells. Toxicol Sci. 2003; 76: 212-9. [46]Thirman MJ, Albrecht JH, Krueger MA, Erickson RR, D.L.Cherwitz, Park SS, et al. Induction of cytochrome CYPIA1 and formation of toxic metabolites of benzo[a]pyrene by rat aorta: a possible role in atherogenesis Natl Acad Sci USA. 1994; 91: 5397-401. [47]Zhang YJ, Weksler BB, Wang L, Schwartz J, Santella RM. Immunohistochemical detection of polycyclic aromatic hydrocarbon-DNA damage in human blood vessels of smokers and non-smokers. Atherosclerosis. 1998; 140: 325-31. [48]Iarmarcovai G, Bonassi S, Botta A, Baan RA, Orsiere T. Genetic polymorphisms and micronucleus formation: a review of the literature. Mutat Res. 2008; 658(3): 215-33. [49]Kiyohara C, Hirohata T, S I. The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Japanese journal of cancer research. 1996; 87(1): 18-24. [50]Engel LS, E T, R P. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol. 2002; 156(2): 95-109. [51]Eagle KA, Guyten RA, Davidoff R. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004; 110(14): e340-e437. [52]Allman K, Shaw L, Hachamovitch R. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002; 39(7). [53]Kip K, Alderman E, Bourassa M. Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. Circulation. 2002; 105(16): 1914-20. [54]Hoffmann D, Hecht SS. Advances in tobacco carcinogenesis. In Chemical Carcinogenesis and Mutagenesis (Cooper, C. S., and Grover, P. L., eds) 1990; pp. 63–102, Raven Press, New York. [55]Bridges BA, Bowyer DE, Hansen ES, Penn A, Wakabayashi K. Report of ICPEMC Subcommittee 7/1. The possible involvement of somatic mutations in the development of atherosclerotic plaques (special issue). Mutat Res. 1990; 239: 143-87. [56]Penn A, Garte SJ, Warren L, Nesta D, Mindich B. Transforming gene in human atherosclerotic plaque DNA. Proc Natl Acad Sci USA. 1986; 83(7951-55). [57]Hall M, Grover PL. Polycyclic aromatic hydrocarbons: metabolism, activation, tumour initiation. In Chemical Carcinogenesis and Mutagenesis (Cooper, C. S., and Grover, P. L., eds) 1990; pp. 327–372, Raven Press, New York. [58]De Flora S, Izzotti A. Mutagenesis and cardiovascular diseases: Molecular mechanisms, risk factors, and protective factors. Mutation Research. 2007; 621: 5-17. [59]van Schooten FJ, Hirvonen A, Maas LM, de Mol BA, Kleinjans JCS, Bell DA, et al. Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking and aromatic DNA-adduct levels in human right artrial tissue. FASEB J. 1998; 12: 1409-17. [60]Sankaranarayanan K, Chakraborty R, Boerwinkle EA, . Ionizing radiation and genetic risks. VI. Chronic multifactorial diseases: a review of epidemiological and genetical aspects of coronary heart disease, essential hypertension and diabetes mellitus. Mutat Res. 1999; 436: 21-57. [61]Guengerich FP. Metabolism of chemical carcinogens. Carcinogenesis. 2000; 21: 345-51. [62]Board PG. Biochemical genetics of glutathione S-transferase in man. Am J Hum Genet. 1991; 33: 36-43. [63]Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993; 85: 1159-64. [64]Hirvonen A, Husgafvel- Pursiainen K, Anttila S, Vainio H. The GSTM1 null genotypes as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis. 1993; 14: 1479-81. [65]Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomark Prev. 2000; 9: 3-28. [66]Boesten LS, Zadelaar AS, Van Nieuwkoop A, Gijbels MJ, deWinther MP, Havekes LM, et al. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. Cardiovasc Res. 2005; 66: 179-85. [67]Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2004; 24: 2137-42. [68]Knaapen AM, Curfs DM, Pachen DM, Gottschalk RW, de Winther MPJ, Daemenc MJ, et al. The environmental carcinogen benzo[a]pyrene induces expression of monocyte-chemoattractant protein-1 in vascular tissue: a possible role in atherogenesis. Mutation Research. 2007; 621: 31-41. [69]Sasaki M, Elrod JW, Jordan P, Itoh M, T. Joh, Minagar A, et al. CYP450 dietary inhibitors attenuate TNFalpha-stimulated endothelial molecule expression and leukocyte adhesion. Am J Physiol Cell Physiol. 2004; 286: C931-9. [70]Sasaki M, Ostanin D, Elrod JW, Oshima T, Jordan P, Itoh M, et al. TNF-alpha-induced endothelial cell adhesion molecule expression is cytochrome P-450 monooxygenase dependent. Am J Physiol Cell Physiol. 2003; 284: C422-8. [71]Hennig B, Meerarani P, Slim R, Toborek M, Daugherty A, Silverstone AE, et al. Proinflammatory properties of coplanar PCBs: in vitro and in vivo evidence. Appl Pharmacol. 2002; 181: 174-83. [72]Dalton TP, Puga A, Shertzer HG. Induction of cellular oxidative stress by aryl hydrocarbon receptor activation. Chem Biol Interact. 2002; 141: 77-95. [73]Johnson CD, Balagurunathan Y, Lu KP, Tadesse M, Falahatpisheh MH, Carroll RJ, et al. Genomic profiles and predictive biological networks in oxidant-induced atherogenesis. Physiol Genomics. 2003; 13: 263-75. [74]Mollerup S, Ryberg D, Hewer A, Phillips DH, Haugen A. Sex Differences in Lung CYP1A1 Expression and DNA Adduct Levels among Lung Cancer Patients. Cancer Res. 59(14): 3317-20. [75]Li S, Pan D. Analysis of polycyclic aromatic hydrocarbons in cooking oil fumes. Arch Envion Occupat Health 1994; 49(2): 119-22. [76]Arnal J-F, Scarabin P-Y, Tremollieres F, Laurell H, Gourdy P. Estrogens in vascular biology and disease: where do we stand today? Curr Opin Lipidol. 2007; 18(5): 554-60. [77]Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean? Circ Res. 2000; 87: 956-60. [78]Arnal JF, Clamens S, Pechet C, Negre-Salvayre A, Allera C, Girolami JP, et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine aortic endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci U S A 1996; 93: 4108-13. [79]Wagner AH, Schroeter MR, Hecker M. 17beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. Faseb J. 2001; 15: 2121-30. [80]Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J, et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ Res. 2002; 90(4): 413-9. [81]Duan R, Porter W, Samudio I, Vyhlidal C, Kladde M, Safe S. Transcriptional activation of c-fos protooncogene by 17beta-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol Endocrinol. 1999; 13(9): 1511-21. [82]Arabaci U, Akdur H, Yigit Z. Effects of smoking on pulmonary functions and arterial blood gases following coronary artery surgery in Turkish patients. Jpn Heart J. 2003; 44: 61-72. [83]Barrera R, Shi W, Amar D, Thaler HT, Gabovich N, Bains MS, et al. Smoking and timing of cessation: impact on pulmonary complications after thoracotomy. Chest. 2005; 127: 1977-83. [84]Al-Sarraf N, Thalib L, Hughes A, Tolan M, Young V, McGovern E. Effect of Smoking on Short-Term Outcome of Patients Undergoing Coronary Artery Bypass Surgery. Ann Thorac Surg. 2008; 86: 517-23.
|